As novel cell surface targets such as glucagon-like peptide-1 (GLP-1) receptors become identified, additional targets for radioisotope-labeled scintigraphy may be developed and integrated for improved detection of pancreatic neuroendocrine tumors [14]. This evidence concerns the gene GLP1R and pancreatic neuroendocrine tumor.